FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
| Publicado en: | Targeted Oncology Vol. 18; no. 2; pp. 269 - 286 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Mar2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=162698966&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 162698966 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17762596 47DQ jtl: Targeted Oncology issn: 17762596 maglogo: N pubinfo: dt: Mar2023 vid: 18 iid: 2 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 162698966 162052020 10.1007/s11523-023-00949-7 162698966 ppf: 269 ppct: 17 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer. aug: au: Caligiuri, Maureen Williams, Grace L. Castro, Jennifer Battalagine, Linda Wilker, Erik Yao, Lili Schiller, Shawn Toms, Angela Li, Ping Pardo, Eneida Graves, Bradford Azofeifa, Joey Chicas, Agustin Herbertz, Torsten Lai, Maria Basken, Joel Wood, Kenneth W. Xu, Qunli Guichard, Sylvie M. affil: Forma Therapeutics, Inc, 300 N Beacon St, 02472, Watertown, MA, USA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|